Since its establishment in 2002, the company has become the leader of domestic antibody biomedical enterprises through long-term unremitting efforts, providing targeted drugs covering major diseases such as anti-tumor, transplantation and autoimmune system, and its application effect has been widely praised by doctors and patients. As a biopharmaceutical company based on R&D, CITIC Guo Jian has successfully established a domestic leading platform for antibody drug research and development and industrial production, mastered cutting-edge core technologies, and has the innovative ability to continuously develop new drugs. The company is developing and clinically selling more than 10 new antibody drugs, which fills many gaps in the domestic biomedical field, and its research and development strength and production capacity are at the international leading level.

Modern production equipment, leading production technology and strict quality control ensure that CITIC Guo Jian provides patients with high-quality pharmaceutical products. As one of the largest mammalian cell culture production bases in Asia, the company has three most advanced 750-liter eukaryotic cell culture production lines and two 3000-liter ones. At the same time, six 5000-liter production lines that meet EU standards are under construction. In addition, the company has specially designed and established a perfect quality management system, covering all factors that affect the quality of drugs, including material management, production management, quality control, quality assurance, equipment and facilities, packaging labels, etc. Its 3000-liter production line adopts international advanced field bus control system (FCS) and process control system (PCS), and Delta VTM digital automation technology applied in this system closely and continuously monitors the whole production process of drugs, so as to eliminate the hidden dangers of product quality to the maximum extent.

Looking forward to the future, CITIC Guo Jian will continue to give full play to its R&D advantages in the field of biotechnology and provide more and more efficient targeted therapeutic drugs for the society.